Weight Watchers Reports Q4 and 2024 Yearly Results
Feb. 27, 2025 WW reported its Q4 and full year 2024 results today. The company’s Board of Directors named Interim President and CEO Tara Comonte,
$33 Billion U.S. Medical Weight Loss Market Dominated by GLP-1 Drugs – New Report
Feb. 27, 2025 Marketdata LLC has published anew 154-page analysis of the U.S. weight loss market, entitled: “The U.S. Medical Weight Loss Market: The Impact of
Eli Lilly To Lower Price of Zepbound Vials, GLP-1 Shortage Is Over
Feb. 25, 2025 Eli Lilly said today that it will offer more doses of its obesity drug Zepbound in vials and lower the prices of
Herbalife Reports 2024 Results, $567 Million Weight Loss U.S. Sales
Feb. 2o, 2025 Herbalife reported Q4 and full year 2024 results. The company sells a significant amount of weight loss and meal replacement products each
Medifast Reports Q4 and Full Year 2024 Results
Feb. 18, 2025 “This past year was a pivotal year for Medifast, as we continued to transform our business to meet the changing nature of
Conflicts in Trump Administration For Support of GLP-1 Meds
Feb. 3, 2025 Support for the wildly popular weight loss meds in the new administration appears to be a question mark. Dr. Oz has publicly
The Party Is Almost Over for GLP-1 Compounders
January 27, 2025 Shortages is that they don’t last forever, and that applies to compounded weight loss meds. After some legal wrangling, the FDA pulled
FDA Says Shortage Is Over, Compounders Have 60-90 Days
Dec. 20, 2024 The Food and Drug Administration said that a nationwide shortage of Eli Lilly’s Zepbound and Mounjaro has been resolved, eliminating the need